ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,481 to 1,500 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Pre-Intervention vs Post-Intervention: Do Not Resuscitate Order2,282 of 3,243

2,127 of 2,823

-5.0 points

-7.2 to -2.7

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Individuals With Pastoral Care Visit1,630 of 3,243

1,765 of 2,823

-12.3 points

-14.7 to -9.8

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Sublingual Administration122 of 3,243

322 of 2,823

-7.6 points

-9.0 to -6.3

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Presence of Order for Opioid Pain Medication2,004 of 3,243

2,056 of 2,823

-11.0 points

-13.4 to -8.7

6,066NCT00234286

Intervention to Improve Care at Life's End

Pre-Intervention vs Post-Intervention: Individuals Administered Antipsychotic Medication224 of 3,243

280 of 2,823

-3.0 points

-4.4 to -1.6

6,066NCT00234286

Intervention to Improve Care at Life's End

Lixisenatide vs Placebo: serious adverse events625 of 3,031

669 of 3,032

-1.4 points

-3.5 to 0.6

6,063NCT01147250

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Cervarix Group vs Placebo Group: Number of Subjects With Serious Adverse Events (SAEs)56 of 3,026

81 of 3,025

-0.8 points

-1.6 to -0.1

6,051NCT00779766

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Cervarix Group vs Placebo Group: Number of Subjects With Medically Significant Conditions (MSC) Regardless of Causal Relationship to Vaccination and Intensity186 of 3,026

185 of 3,025

0.0 points

-1.2 to 1.2

6,051NCT00779766

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Cervarix Group vs Placebo Group: deaths from any cause0 of 3,026

3 of 3,025

-0.1 points

-0.3 to 0.0

6,051NCT00779766

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Cervarix Group vs Placebo Group: serious adverse events56 of 3,026

81 of 3,025

-0.8 points

-1.6 to -0.1

6,051NCT00779766

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Linagliptin vs Glimepiride: deaths from any cause308 of 3,023

336 of 3,010

-1.0 points

-2.5 to 0.6

6,033NCT01243424

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Linagliptin vs Glimepiride: serious adverse events1,403 of 3,023

1,448 of 3,010

-1.7 points

-4.2 to 0.8

6,033NCT01243424

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Electronic AKI Alert vs Usual Care: Mortality272 of 3,059

265 of 2,971

-0.0 points

-1.5 to 1.4

6,030NCT02753751

Optimizing Electronic Alerts for Acute Kidney Injury

Electronic AKI Alert vs Usual Care: Number of Subjects With Chart Documentation of AKI2,141 of 3,059

1,871 of 2,971

7.0 points

4.6 to 9.4

6,030NCT02753751

Optimizing Electronic Alerts for Acute Kidney Injury

Electronic AKI Alert vs Usual Care: Dialysis106 of 3,059

93 of 2,971

0.3 points

-0.6 to 1.2

6,030NCT02753751

Optimizing Electronic Alerts for Acute Kidney Injury

Electronic AKI Alert vs Usual Care: AKI Progression487 of 3,059

461 of 2,971

0.4 points

-1.4 to 2.2

6,030NCT02753751

Optimizing Electronic Alerts for Acute Kidney Injury

Electronic AKI Alert vs Usual Care: deaths from any cause272 of 3,059

265 of 2,971

-0.0 points

-1.5 to 1.4

6,030NCT02753751

Optimizing Electronic Alerts for Acute Kidney Injury

Electronic AKI Alert vs Usual Care: Composite of Progression of AKI, Inpatient Dialysis, or Inpatient Death653 of 3,059

622 of 2,971

0.4 points

-1.7 to 2.5

6,030NCT02753751

Optimizing Electronic Alerts for Acute Kidney Injury

HPV Self Testing vs HPV at Health Centers: Acceptability2,616 of 3,049

0 of 2,964

85.8 points

84.5 to 87.0

6,013NCT02095561

Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake

Finerenone (BAY94-8862) vs Placebo: First Occurrence of Renal Composite Events75 of 3,003

55 of 2,998

0.7 points

-0.1 to 1.4

6,001NCT04435626

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=75

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00234286-7d9830a3",
        "title": "Pre-Intervention vs Post-Intervention: Do Not Resuscitate Order",
        "summary": "2282 of 3243 against 2127 of 2823; risk difference -5.0 points, 95% interval -7.2 to -2.7; NCT00234286, Intervention to Improve Care at Life's End",
        "record": "/library/comparisons/NCT00234286-7d9830a3",
        "nct_id": "NCT00234286",
        "kind": "outcome",
        "participants": 6066,
        "risk_difference": {
          "value": -0.04978433070755195,
          "lower": -0.07205804302693433,
          "upper": -0.027359539539710938
        },
        "group_1": "2,282 of 3,243",
        "group_2": "2,127 of 2,823",
        "difference": "-5.0 points",
        "interval": "-7.2 to -2.7",
        "trial_title": "Intervention to Improve Care at Life's End"
      },
      {
        "id": "NCT00234286-c9eb75e8",
        "title": "Pre-Intervention vs Post-Intervention: Individuals With Pastoral Care Visit",
        "summary": "1630 of 3243 against 1765 of 2823; risk difference -12.3 points, 95% interval -14.7 to -9.8; NCT00234286, Intervention to Improve Care at Life's End",
        "record": "/library/comparisons/NCT00234286-c9eb75e8",
        "nct_id": "NCT00234286",
        "kind": "outcome",
        "participants": 6066,
        "risk_difference": {
          "value": -0.12260036576777966,
          "lower": -0.14726389494180764,
          "upper": -0.09769609019903666
        },
        "group_1": "1,630 of 3,243",
        "group_2": "1,765 of 2,823",
        "difference": "-12.3 points",
        "interval": "-14.7 to -9.8",
        "trial_title": "Intervention to Improve Care at Life's End"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=76",
  "request_id": "Jmmd8oCyrILnJbHU"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?